NovaGo Therapeutics Overview
- Year Founded
-
2015
- Status
-
Private
- Employees
-
10
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$29.7M
- Investors
-
6
NovaGo Therapeutics General Information
Description
Developer of human antibody therapeutics intended to enhance nerve growth and regeneration for patients with spinal cord injuries. The company's therapy focuses on blocking the Nogo-A receptor, which inhibits nerve growth, thereby facilitating nerve repair and improving functional recovery, enabling healthcare providers to offer advanced treatment options for individuals affected by severe neurological disorders.
Contact Information
Website
www.novagotherapeutics.comCorporate Office
- Wagistrasse 27
- Schlieren
- 8952 Zürich
- Switzerland
Corporate Office
- Wagistrasse 27
- Schlieren
- 8952 Zürich
- Switzerland
NovaGo Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Later Stage VC (Series B) | 31-Aug-2026 | $29.7M | Completed | Clinical Trials - Phase 1 | ||
| 4. Later Stage VC (Series B) | Cancelled | Clinical Trials - Phase 1 | ||||
| 3. Early Stage VC (Series A) | 04-Mar-2019 | Completed | Clinical Trials - Phase 1 | |||
| 2. Accelerator/Incubator | 01-Jan-2016 | Completed | Clinical Trials - Phase 1 | |||
| 1. University Spin-Out | 01-Jan-2015 | Completed | Pre-Clinical Trials |
NovaGo Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Preference |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
NovaGo Therapeutics Patents
NovaGo Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026041734-A1 | Methods for treating neurological disorders using anti-nogo-a antibodies | Pending | 22-Aug-2024 | ||
| US-12662528-B2 | Anti-nogo-a antibodies and methods of making and using thereof | Active | 24-Oct-2019 | ||
| AU-2020370751-A1 | Novel anti-nogo-a antibodies | Pending | 24-Oct-2019 | ||
| CA-3158491-A1 | Novel anti-nogo-a antibodies | Pending | 24-Oct-2019 | ||
| EP-4048692-A2 | Novel anti-nogo-a antibodies | Pending | 24-Oct-2019 | C07K16/22 |
NovaGo Therapeutics Signals
NovaGo Therapeutics Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Swiss Paraplegic Foundation | Corporation | |||
| The Wings for Life foundation | Corporation | |||
| Kinled Holding | Family Office | Minority | ||
| Neurimmune | Corporation | Minority | ||
| Pureos Bioventures | Venture Capital | Minority |
NovaGo Therapeutics FAQs
-
When was NovaGo Therapeutics founded?
NovaGo Therapeutics was founded in 2015.
-
Where is NovaGo Therapeutics headquartered?
NovaGo Therapeutics is headquartered in Zürich, Switzerland.
-
What is the size of NovaGo Therapeutics?
NovaGo Therapeutics has 10 total employees.
-
What industry is NovaGo Therapeutics in?
NovaGo Therapeutics’s primary industry is Drug Discovery.
-
Is NovaGo Therapeutics a private or public company?
NovaGo Therapeutics is a Private company.
-
What is NovaGo Therapeutics’s current revenue?
The current revenue for NovaGo Therapeutics is .
-
How much funding has NovaGo Therapeutics raised over time?
NovaGo Therapeutics has raised $41.4M.
-
Who are NovaGo Therapeutics’s investors?
Swiss Paraplegic Foundation, The Wings for Life foundation, Kinled Holding, Neurimmune, and Pureos Bioventures are 5 of 6 investors who have invested in NovaGo Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process